Maryland Innovation Initiative (MII)

Capsulomics, LLC is a biotechnology company focused on developing and manufacturing DNA tests for the early detection of upper gastrointestinal (GI) cancers, particularly esophageal cancer and its precancerous condition, Barrett’s esophagus. Founded in 2018 and based in Halethorpe, Maryland, Capsulomics aims to address the diagnostic and prognostic uncertainties associated with GI diseases. By providing advanced diagnostic solutions, the company enables healthcare professionals to prevent, detect, and treat these conditions more effectively, ultimately enhancing patient outcomes.

TEDCO is an independent organization established in 1998 and located in Columbia, Maryland. It serves as the leading source of entrepreneurial business assistance and seed funding for the development of startup companies within Maryland's innovation economy. TEDCO focuses on early-stage companies across various sectors, including software, technology, energy equipment, life sciences, and oncology. Its mission is to foster innovation and economic growth in Maryland by supporting the growth of startups and enhancing the state's position in the entrepreneurial landscape.

Mind-X Corp. specializes in designing and developing interfaces for spatial computing applications by integrating neurotechnology, augmented reality, and artificial intelligence. Founded in 2017 by Geoffrey Ling and Julia Brown, the company focuses on creating a framework that combines brain-computer interfaces with advanced AI capabilities. Headquartered in Bethesda, Maryland, Mind-X aims to enhance user interaction with technology through innovative software solutions that leverage cutting-edge advancements in neuroscience and computing.

Sonoval LLC is a biotechnology company based in Baltimore, Maryland, focused on developing innovative protein-based therapies for cancer treatment. Established in 2017, the company is working on a novel drug, SON-211, which targets T-cell lymphomas and various solid tumors. This therapy operates by binding to receptors on tumor cells, delivering a toxic payload that not only destroys cancerous cells but also helps eliminate immune system suppressors, thereby enhancing the body's own anticancer defenses. Through its advanced platform, Sonoval aims to provide effective immunotherapies that can significantly improve treatment outcomes for patients with challenging cancer types.

ACTIVEcharge, based in Baltimore, specializes in developing innovative systems that harness wasted vibrational and kinematic energy to generate electrical power for battery-free sensor operations, particularly in wind-powered turbines. The company’s technology integrates a predictive analytics software engine that monitors hard-to-reach locations, identifying structural and operational issues before they escalate into significant problems. This proactive approach allows clients to implement actionable insights autonomously, enhancing equipment uptime and ultimately boosting profitability over the equipment's lifespan. By focusing on sustainability and efficiency, ACTIVEcharge offers solutions that address modern operational challenges in various industries.

OncoSTING LLC, founded in 2018 and based in Baltimore, Maryland, specializes in developing innovative therapies for bladder cancer. The company's approach integrates the established efficacy of BCG immunotherapy with a novel delivery system for potent STING agonists, which aims to enhance treatment effectiveness while minimizing the adverse effects typically associated with traditional BCG therapy. By focusing on this combination, OncoSTING seeks to provide a more effective and safer treatment option for patients suffering from bladder cancer.

Renalert, based in Baltimore, specializes in the early detection of acute kidney injury (AKI) through a sophisticated monitoring system. This system precisely measures urine output while correlating these values with vital signs such as blood pressure and oxygenation. By employing a proprietary algorithm, Renalert's technology enables medical professionals to estimate renal perfusion and detect early declines in kidney function. This innovation aims to prevent needless fatalities associated with AKI by allowing timely intervention and treatment.